JMIR Publications

ABSTRACT

Background:

Ballistocardiogram (BCG) is a non-contact, non-invasive method for monitoring cardiac activity. It has shown potential in various medical applications, particularly in the field of coronary heart disease (CHD). As interest in this technology grows, it is crucial to understand its advancements and benefits in diagnosing, treating, and preventing CHD.

Objective:

The objective of this research is to explore the advancements and merits of BCG's application in the diagnosis, treatment, and prevention of CHD. By analyzing relevant literature, this study aims to provide insights into the potential of BCG as a diagnostic tool for CHD.

Methods:

Following the PRISMA 2020 guidelines, a literature search and selection were conducted on PubMed, Scopus, Web of Science, and Cochrane databases. A total of 500 articles were retrieved, and 266 were selected based on their titles, abstracts, and keywords. Further filtering excluded non-English articles, animal experiments, and review articles, resulting in a final selection of 38 articles for inclusion in the study.

Results:

Among the 38 articles, 22 focused on the application of BCG in acute coronary syndrome. These articles explored various aspects, including BCG waveforms in patients with acute myocardial infarction (MI), the diagnosis of acute coronary syndrome (ACS), and the relationship between age and the rate of abnormal BCG waveforms. The remaining articles covered the effects of drugs, emotions, exercise, and other variables on BCG recordings in patients with CHD. These studies highlighted BCG's high accuracy in diagnosing CHD compared to traditional methods like electrocardiogram (ECG).

Conclusions:

Overall, as an emerging technology, BCG offers a promising framework for the future development of diagnosis and prevention of CHD. Its unique ability to provide valuable insights into cardiac function and its potential to detect early signs of CHD make it a valuable tool for healthcare professionals. With further research and development, BCG could revolutionize the way we diagnose and manage CHD, ultimately improving patient outcomes and quality of life.